Search Results - "Mestres, Joan Albanell"
-
1
716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer
Published in Journal for immunotherapy of cancer (01-11-2023)“…BackgroundDespite advances made in management of patients with HER2-driven solid tumors, unmet need remains for novel approaches to improve patient outcomes…”
Get full text
Journal Article -
2
Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer
Published in Biomedicine & pharmacotherapy (01-01-2009)“…Abstract Women are at considerable risk of recurrence in the first few years following initial treatment for early breast cancer. To reduce the risk of…”
Get full text
Journal Article -
3
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
Published in Genome medicine (28-03-2018)“…While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important…”
Get full text
Journal Article -
4
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Published in JNCI : Journal of the National Cancer Institute (01-12-2015)“…There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could…”
Get full text
Journal Article -
5
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer
Published in European journal of cancer (1990) (01-10-2016)“…Abstract Purpose The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive information in oestrogen receptor positive (ER+) early breast…”
Get full text
Journal Article -
6
A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial-mesenchymal transition
Published in Nature cell biology (01-08-2009)“…Epithelial-mesenchymal transition (EMT) is essential for organogenesis and is triggered during carcinoma progression to an invasive state. Transforming growth…”
Get full text
Journal Article -
7
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
Published in Scientific reports (25-01-2017)“…A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab…”
Get full text
Journal Article -
8
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Published in Clinical cancer research (15-11-2017)“…Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify…”
Get full text
Journal Article -
9
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
Published in Frontiers in immunology (13-11-2017)“…Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of…”
Get full text
Journal Article -
10
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Published in Clinical cancer research (01-07-2016)“…Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However,…”
Get full text
Journal Article -
11
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Published in Clinical & translational oncology (01-07-2018)“…This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative…”
Get full text
Journal Article -
12
FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth
Published in Nature communications (05-04-2016)“…The mechanisms that allow breast cancer (BCa) cells to metabolically sustain rapid growth are poorly understood. Here we report that BCa cells are dependent on…”
Get full text
Journal Article -
13
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
Published in British journal of cancer (14-10-2014)“…Background: In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer…”
Get full text
Journal Article -
14
Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells
Published in Nature communications (31-07-2018)“…Delta ligands regulate Notch signaling in normal intestinal stem cells, while Jagged1 activates Notch in intestinal adenomas carrying active β-catenin. We used…”
Get full text
Journal Article -
15
Abstract P4-10-17: Baseline and pharmacodynamic changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis of the PARSIFAL-1 trial
Published in Cancer research (Chicago, Ill.) (15-02-2020)“…BACKGROUND: Palbociclib in combination with endocrine therapy (ET) is the first- or second-line standard of care for patients (pts) with hormone receptor…”
Get full text
Journal Article -
16
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
Published in Oncotarget (30-06-2015)“…We aimed to assess MET intratumoral heterogeneity and its potential impact on biomarker-based patient selection as well as potential surrogate biomarkers of…”
Get full text
Journal Article -
17
Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?
Published in Annals of oncology (01-06-2015)Get full text
Journal Article -
18
-
19
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
Published in Oncotarget (28-03-2017)“…PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal…”
Get full text
Journal Article -
20
Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
Published in Oncotarget (01-01-2014)“…NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer…”
Get full text
Journal Article